A new biomedicalmaterial of type A recombinant humanized collagen type Ⅲ

QIAO Shaojun; PEI Yu; LAN Xiaobin

doi:10.12405/j.issn.2097-1486.2024.01.002

您当前的位置：

首页 >

文章列表页 >

A new biomedicalmaterial of type A recombinant humanized collagen type Ⅲ

更新时间：2024-08-15

- A new biomedicalmaterial of type A recombinant humanized collagen type Ⅲ
- Emerging Science and Technology(Nat.Sci.Ed.) Vol. 3, Issue 1, Pages: 9-17(2024)
- 作者机构：
  
  功能蛋白山西省重点实验室，山西锦波生物医药股份有限公司，山西太原 030032
- 作者简介：
- 基金信息：
- DOI：10.12405/j.issn.2097-1486.2024.01.002
  CLC： R318.08
- Published：15 March 2024，
  
  Received：19 February 2024，
  
  Revised：10 March 2024，
- 稿件说明：
扫描看全文
乔绍俊,裴育,兰小宾.新型生物医用材料A型重组Ⅲ型人源化胶原蛋白[J].新兴科学和技术趋势,2024,3(1):9-17.

QIAO Shaojun,PEI Yu,LAN Xiaobin.A new biomedicalmaterial of type A recombinant humanized collagen type Ⅲ[J].Emerging Science and Technology,2024,3(1):9-17.
乔绍俊,裴育,兰小宾.新型生物医用材料A型重组Ⅲ型人源化胶原蛋白[J].新兴科学和技术趋势,2024,3(1):9-17. DOI： 10.12405/j.issn.2097-1486.2024.01.002.

QIAO Shaojun,PEI Yu,LAN Xiaobin.A new biomedicalmaterial of type A recombinant humanized collagen type Ⅲ[J].Emerging Science and Technology,2024,3(1):9-17. DOI： 10.12405/j.issn.2097-1486.2024.01.002.

摘要

胶原蛋白是人体重要的细胞外基质成分，具有着特殊的“三螺旋”结构，既是结构蛋白又是功能蛋白，也是重要的生物医用材料。目前市场主流的胶原蛋白主要是通过动物组织提取获得，无法避免种属差异带来的免疫原性及动物病原体风险，同时，低丰度胶原蛋白无法通过动物组织提取获得。利用合成生物制备重组胶原蛋白是胶原蛋白产业发展趋势，尤其是通过功能区策略制备的重组人源化胶原蛋白，不仅能够避免免疫原性，还可保障胶原良好的生物相容性与活性。本文重点介绍山西锦波生物医药股份有限公司A型重组Ⅲ型人源化胶原蛋白新材料的研发历程，同时分析其可能的创新应用场景。首先，通过高通量筛选获得具有164.88°特殊三螺旋结构的人Ⅲ型胶原蛋白核心功能区。随后对该功能区进行16次线性重复，获得A型重组Ⅲ型人源化胶原蛋白，其氨基酸序列中无任何外源非人胶原蛋白序列。经多种方法检测，其具有三螺旋结构，与细胞互作时不进入细胞，通过改善细胞外基质，有效发挥修复再生功效，有望在皮肤损伤修复、妇科、心血管科、骨科、口腔科等领域发挥重要作用。目前，其在重组胶原注射领域占据主要市场地位，突破40年仅有动物胶原注射的时代。

Abstract

Collagen is an important component of extracellular matrix in human body， with the special "triple helix" structure. Collagen is both structural protein and functional protein. And it is also an important biomedical material. Currently， collagen is mainly obtained on the market through animal extraction， which cannot avoid the risk of immunogenicity caused by species differences and the risk of animal pathogens infection. Meanwhile， low abundance collagen cannot be obtained through animal tissue extraction. Recombinant humanized collagen， especially through functional region strategies， not only avoids immunogenicity， but also guarantees good collagen biocompatibility and activity. This paper focuses mainly on the research development of the new material of type A recombinant humanized collagen type Ⅲ， and analyzes its possible innovative application scenarios. Firstly， we obtained the core functional region of human type Ⅲ collagen with a special 164.88° triple helix structure by high-throughput screening. Subsequently， we performed 16 linear repeats of the core functional region to obtain A-type recombinant humanized collagen type Ⅲ without any exogenous non-human collagen sequence in its amino acid sequence. A-type recombinant humanized collagen type Ⅲ has a triple helix structure and does not enter the cell when interacting with the cell. A-type recombinant humanized collagen type Ⅲ effectively exerts repair and regeneration efficacy by improving the extracellular matrix， which is expected to play an important role in the fields of skin damage repair， gynaecology， cardiovascular， orthopaedics， stomatology and so on. Now， A-type recombinant humanized collagen type Ⅲ occupies a major position in the market in the field of injectable recombinant collagen， which is a breakthrough of 40 years of only-animal collagen injections.

关键词

合成生物新型生物医用材料人Ⅲ型胶原蛋白重组人源化胶原蛋白A型三螺旋结构

Keywords

synthetic organismsbiomedical materialshuman collagen type Ⅲrecombinant humanized collagenType Atriple helix structure

references

杨晓晶. 国内高品质胶原蛋白行业发展白皮书［M］. 北京：商务部国际贸易经济合作研究院， 2022.006.

杨彧. 锦波生物“重组Ⅲ型人源化胶原蛋白冻干纤维”获准上市［N］. 山西日报，2021-07-27（001）.

胡康，张伟. 胶原蛋白作为医用生物材料对缺损组织修复、再生及重建的作用与意义［J］. 中国组织工程研究， 2019， 23（2）： 317-322. DOI：10.3969/j.issn.2095-4344.0650http://dx.doi.org/10.3969/j.issn.2095-4344.0650.

WANG J， QIU H， XU Y， et al. The biological effect of recombinant humanized collagen on damaged skin induced by UV-photoaging： An in vivo study［J］. Bioactive Materials， 2022（11）：154-165. DOI：10.1016/j.bioactmat.2021.10.004http://dx.doi.org/10.1016/j.bioactmat.2021.10.004.

国家药品监督管理局. 关于发布重组胶原蛋白生物材料命名指导原则的通告（2021年第21号）［EB］. （2021-03-15）［2024-01-09］. https：//www.nmpa.gov.cn/xxgk/ggtg/ylqxggtg/ylqxqtggtg/20210315175109170.htmlhttps://www.nmpa.gov.cn/xxgk/ggtg/ylqxggtg/ylqxqtggtg/20210315175109170.html

国家药品监督管理局. 《重组胶原蛋白生物材料命名指导原则》解读［EB］. （2023-01-29）［2024-01-09］. https：//www.nifdc.org.cn/nifdc/bshff/ylqxbzhgl/qxggtzh/ggqt/20230129133404449638.htmlhttps://www.nifdc.org.cn/nifdc/bshff/ylqxbzhgl/qxggtzh/ggqt/20230129133404449638.html

HUA C， ZHU Y， XU W， et al. Characterization by high-resolution crystal structure analysis of a triple-helix region of human collagen type Ⅲ with potent cell adhesion activity［J］. Biochem Biophys Res Commun， 2019， 508（4）：1018-1023. DOI：10.1016/j.bbrc.2018.12.018http://dx.doi.org/10.1016/j.bbrc.2018.12.018.

YANG X.Polypeptide， process for the production thereof and use thereof［P］. 美国专利：US11396537， 2022-07-26.

杨霞. 多肽、其生产方法和用途［P］. 中国专利： CN109293783B， 2019-10-11.

MAXWELL C A， WESS T J， KENNEDY C J. X-ray diffraction study into the effects of liming on the structure of collagen［J］. Biomacromolecules， 2006， 7（8）：2321-2326. DOI：10.1021/bm060250thttp://dx.doi.org/10.1021/bm060250t.

邱加恩，李青峰. 注射填充材料的应用［J］. 组织工程与重建外科杂志， 2015， 11（05）： 346-349. DOI：10.3969/j.issn.1673-0364.2015.05.016http://dx.doi.org/10.3969/j.issn.1673-0364.2015.05.016.

国家药品监督管理局. 重组重组Ⅲ型人源化胶原蛋白冻干纤维获批上市［EB］. （2021-06-29）［2024-01-09］. https：//www.nmpa.gov.cn/yaowen/ypjgyw/ylqxyw/20210629141635133.htmlhttps://www.nmpa.gov.cn/yaowen/ypjgyw/ylqxyw/20210629141635133.html.

田春英. 2021年中国医药生物技术十大进展评选结果揭晓［J］. 中国医药生物技术， 2022， 17（1）： 2-3.DOI：10.3969/j.issn.1673-713X.2022.01.002http://dx.doi.org/10.3969/j.issn.1673-713X.2022.01.002.

LONG L Y， HU C， LIU W Q， et al. Injectable multifunctional hyaluronic acid/methylcellulose hydrogels for chronic wounds repairing［J］. Carbohydrate Polymers， 2022， 289： 119456. DOI：10.1016/j.carbpol.2022.119456http://dx.doi.org/10.1016/j.carbpol.2022.119456.

CHEN N Y， LI M Y， WU H S， et al. An extracellular matrix-mimetic coating with dual bionics for cardiovascular stents［J］. Regenerative Biomaterials， 2023， 10： rbad055. DOI：10.1093/RB/RBAD055http://dx.doi.org/10.1093/RB/RBAD055.

HU C， LIU W Q， LONG L Y， et al. Regeneration of infarcted hearts by myocardial infarction-responsive injectable hydrogels with combined anti-apoptosis， anti-inflammatory and pro-angiogenesis properties［J］. Biomaterials， 2022， 290： 121849. DOI：10.1016/j.biomaterials.2022.121849http://dx.doi.org/10.1016/j.biomaterials.2022.121849.

YOU S， LIU S B， DONG X J， et al. Intravaginal Administration of Human Type Ⅲ Collagen-Derived Biomaterial with High Cell-Adhesion Activity to Treat Vaginal Atrophy in Rats［J］. Acs Biomaterials Science & Engineering， 2020， 6（4）：1977-1988. DOI：10.1021/acsbiomaterials.9b01649http://dx.doi.org/10.1021/acsbiomaterials.9b01649.

LI H， YOU S， YANG X， et al. Injectable recombinant human collagen-derived material with high cell adhesion activity limits adverse remodelling and improves pelvic floor function in pelvic floor dysfunction rats［J］. Mater Sci Eng C Mater Biol Appl， 2022， 134： 1112715. DOI：10.1016/j.msec.2022.112715http://dx.doi.org/10.1016/j.msec.2022.112715.

YOU S， ZHU Y， LI H， et al. Recombinant humanized collagen remodels endometrial immune microenvironment of chronic endometritis through macrophage immunomodulation［J］. Regenerative Biomaterials， 2023， 10： rbad033. DOI：10.1093/RB/RBAD033http://dx.doi.org/10.1093/RB/RBAD033.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰